Fig. 3From: The prognosis impact of hyperthermic intraperitoneal chemotherapy (HIPEC) plus cytoreductive surgery (CRS) in advanced ovarian cancer: the meta-analysisSensitive analysis between HIPEC group and non-HIPEC group a OS b PFSBack to article page